Request Deal Involvement
Prime Therapeutics completed the acquisition of Magellan Rx from Centene for $1.35bn.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
financial advisors
Allen & Company
financial advisors
Evercore
financial advisors
Barclays
legal advisors
Skadden Arps Slate Meagher & Flom
financial advisors
Solomon Partners
legal advisors
McDermott Will & Emery
legal advisors
Fox Rothschild
or
Principals
vendor
CENTENE CORPORATION
bidder
PRIME THERAPEUTICS LLC
target
MAGELLAN RX
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite